Drug Profile
Alendronic acid liposomal - BIOrest
Alternative Names: LABR-312Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator BIOrest
- Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Monocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Coronary artery restenosis in Israel (IV)
- 08 Sep 2021 No development reported - Phase-II for Coronary artery restenosis in United Kingdom (IV)
- 11 Jan 2016 BIOrest plans a phase II trial for Coronary artery restenosis in Poland, Canada and United Kingdom (NCT02645799)